Meyka Pro banner
CellSeed Inc.

CellSeed Inc. Fundamental Analysis (JPX: 7776.T)

7776.TJPX
HealthcareBiotechnology
¥234.00
¥2.00(0.86%)
Japanese Market opens in 9h 49m

CellSeed Inc. Fundamental Analysis (JPX: 7776.T)

CellSeed Inc. (JPX: 7776.T) shows weak financial fundamentals with a PE ratio of -8.05, profit margin of -15.76%, and ROE of -66.94%. The company generates $0.1B in annual revenue with weak year-over-year growth of -56.71%.

Key Strengths

Cash Position19.74%
PEG Ratio-10.19
Current Ratio10.41

Areas of Concern

ROE-66.94%
Operating Margin-14.72%
We analyze 7776.T's fundamental strength across five key dimensions.

The stock receives a Fundamental Health Score of -1276.0/100 based on profitability, valuation, growth, and balance sheet metrics. The F grade reflects weak fundamentals and significant financial concerns.

Fundamental Health Score

F
-1276.0/100

We analyze 7776.T's fundamental strength across five key dimensions:

Efficiency Score

Weak

7776.T struggles to generate sufficient returns from assets.

ROA > 10%
-51.01%

Valuation Score

Excellent

7776.T trades at attractive valuation levels.

PE < 25
-8.05
PEG Ratio < 2
-10.19

Growth Score

Weak

7776.T faces weak or negative growth trends.

Revenue Growth > 5%
-56.71%
EPS Growth > 10%
-23.72%

Financial Health Score

Excellent

7776.T maintains a strong and stable balance sheet.

Debt/Equity < 1
0.07
Current Ratio > 1
10.41

Profitability Score

Weak

7776.T struggles to sustain strong margins.

ROE > 15%
-6694.10%
Net Margin ≥ 15%
-15.76%
Positive Free Cash Flow
No

Key Financial Metrics

Is 7776.T Expensive or Cheap?

P/E Ratio

7776.T trades at -8.05 times earnings. This suggests potential undervaluation.

-8.05

PEG Ratio

When adjusting for growth, 7776.T's PEG of -10.19 indicates potential undervaluation.

-10.19

Price to Book

The market values CellSeed Inc. at 5.12 times its book value. This suggests the stock is fully valued or overvalued on an asset basis.

5.12

EV/EBITDA

Enterprise value stands at -10.85 times EBITDA. This is generally considered low.

-10.85

How Well Does 7776.T Make Money?

Net Profit Margin

For every $100 in sales, CellSeed Inc. keeps $-15.76 as profit after all expenses.

-15.76%

Operating Margin

Core operations generate -14.72 in profit for every $100 in revenue, before interest and taxes.

-14.72%

ROE

Management delivers $-66.94 in profit for every $100 of shareholder equity.

-66.94%

ROA

CellSeed Inc. generates $-51.01 in profit for every $100 in assets, demonstrating efficient asset deployment.

-51.01%

Following the Money - Real Cash Generation

Operating Cash Flow

CellSeed Inc. generates limited operating cash flow of $0.00, signaling weaker underlying cash strength.

$0.00

Free Cash Flow

CellSeed Inc. generates weak or negative free cash flow of $0.00, restricting financial flexibility.

$0.00

FCF Per Share

Each share generates $0.00 in free cash annually.

$0.00

FCF Yield

7776.T converts 0.00% of its market value into free cash.

0.00%

Financial Ratios Analysis

Valuation Ratios

P/E Ratio

Price to earnings ratio

-8.05

vs 25 benchmark

PEG Ratio

Price/earnings to growth ratio

-10.19

vs 25 benchmark

P/B Ratio

Price to book value ratio

5.12

vs 25 benchmark

P/S Ratio

Price to sales ratio

134.19

vs 25 benchmark

Financial Health

Debt/Equity

Total debt to shareholders' equity

0.07

vs 25 benchmark

Current Ratio

Current assets to current liabilities

10.41

vs 25 benchmark

Efficiency Ratios

ROE

Return on equity percentage

-0.67

vs 25 benchmark

ROA

Return on assets percentage

-0.51

vs 25 benchmark

ROCE

Return on capital employed

-0.52

vs 25 benchmark

How 7776.T Stacks Against Its Sector Peers

Metric7776.T ValueSector AveragePerformance
P/E Ratio-8.0532.14 Better (Cheaper)
ROE-66.94%550.00% Weak
Net Margin-1575.63%30133.00% Weak
Debt/Equity0.070.56 Strong (Low Leverage)
Current Ratio10.415.70 Strong Liquidity
ROA-51.01%3.00% Weak

7776.T outperforms its industry in 3 out of 6 key metrics, but lagging in ROE.

Historical Growth Performance

5-Year Growth Trajectory

This section reviews CellSeed Inc.'s 5-year compound annual growth rate (CAGR) and compares its performance against the typical investment style of its industry.

Revenue CAGR

-82.86%

Industry Style: Defensive, Growth, Innovation

Declining

EPS CAGR

42.46%

Industry Style: Defensive, Growth, Innovation

High Growth

FCF CAGR

42.34%

Industry Style: Defensive, Growth, Innovation

High Growth

Fundamental Analysis FAQ